XACDURO (COPACKAGED)
Growthsulbactam and durlobactam
NDAINTRAVENOUSPOWDERPriority Review
Approved
May 2023
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XACDURO is a copackaged intravenous powder combination of sulbactam and durlobactam, a novel beta-lactam/beta-lactamase inhibitor combination designed to treat serious bacterial infections. Durlobactam is a next-generation beta-lactamase inhibitor that protects sulbactam from enzymatic degradation. The drug targets gram-negative and gram-positive pathogens with resistance mechanisms.
Growth9.5 years to LOE
Early-stage IV antibiotic in growth phase with significant opportunity to build market share in the hospital-based infectious disease space.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on XACDURO offers the opportunity to build a new brand in the high-value hospital IV antibiotic space with a novel mechanism and 9+ years of patent protection. This growth-stage asset provides career visibility in both commercial execution and medical education for infectious disease specialists.
Brand ManagerField Sales Representative
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.